Galapagos Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Paul Stoffels

Amministratore delegato

€2.0m

Compenso totale

Percentuale dello stipendio del CEO	38.0%
Mandato del CEO	2.6yrs
Proprietà del CEO	n/a
Durata media del management	2.5yrs
Durata media del Consiglio di amministrazione	2.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Paul Stoffels rispetto agli utili di Galapagos?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-€61m
Jun 30 2024	n/a	n/a	€32m
Mar 31 2024	n/a	n/a	€31m
Dec 31 2023	€2m	€750k	-€4m
Sep 30 2023	n/a	n/a	-€153m
Jun 30 2023	n/a	n/a	-€46m
Mar 31 2023	n/a	n/a	-€69m
Dec 31 2022	€1m	€563k	-€71m

Compensazione vs Mercato: La retribuzione totale di Paul ($USD 2.13M ) è circa la media per le aziende di dimensioni simili nel mercato UK ($USD 2.12M ).

Compensazione vs guadagni: La retribuzione di Paul è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Paul Stoffels (62 yo)

2.6yrs

Mandato

€1,971,286

Compensazione

Dr. Paulus A. Stoffels, also known as Paul, Ph.D. M.D. is Chief Executive Officer of Galapagos NV since April 01, 2022 and also serves as its Chairman since April 26, 2022 and also serves as its Interim He...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Paulus Stoffels	CEO, Chairman	2.6yrs	€1.97m	Nessun dato
Thad Huston	Executive VP	1.3yrs	Nessun dato	Nessun dato
Sofie Van Gijsel	Head of Investor Relations	no data	Nessun dato	Nessun dato
Valeria Cnossen	Executive VP & General Counsel	2.8yrs	Nessun dato	Nessun dato
Marieke Vermeersch	Head of Corporate Communication	no data	Nessun dato	Nessun dato
Annelies Missotten	Executive VP & Chief Human Resources Officer	no data	Nessun dato	Nessun dato
Ellen Aar	Head of Development	no data	Nessun dato	Nessun dato
Philippe Alen	Senior VP & Head of Business Development	2.8yrs	Nessun dato	Nessun dato
Alice Dietrich	Head of Medical Affairs	no data	Nessun dato	Nessun dato
Pierre Raboisson	Head of Small Molecules Discovery & Senior VP	2.4yrs	Nessun dato	Nessun dato
Patrik Ringblom	Head of Strategy & US Lead	1.1yrs	Nessun dato	Nessun dato
Jeevan Shetty	Head of Clinical Development Oncology	no data	Nessun dato	Nessun dato

2.5yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di 0JXZ è considerato esperto (durata media dell'incarico 2.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Paulus Stoffels	CEO, Chairman	2.6yrs	€1.97m	Nessun dato
Simon Sturge	Independent Non-Executive Director	1.2yrs	€32.37k	0.00027% € 4.5k
Jerome Contamine	Lead Independent Non-Executive Director	2.6yrs	€150.00k	0.0015% € 25.8k
Andrew Dickinson	Non-Executive Non-Independent Director	less than a year	Nessun dato	Nessun dato
Linda Higgins	Non-Executive Non-Independent Director	5.1yrs	Nessun dato	Nessun dato
Susanne Schaffert	Non-Executive Independent Director	1.4yrs	€59.85k	0.00055% € 9.3k
Oleg Nodelman	Non-Executive Non-Independent Director	less than a year	Nessun dato	Nessun dato
Peter Guenter	Independent Non-Executive Director	5.6yrs	€115.00k	0.0030% € 50.8k
Elisabeth Svanberg	Independent Non-Executive Director	4.6yrs	€138.75k	0.0029% € 48.1k

2.6yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 0JXZ non è considerato esperto (durata media del mandato 2.6 anni), il che suggerisce un nuovo consiglio.

Galapagos Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Galapagos NV Announces Board Changes

Galapagos NV Announces Board Changes

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

High number of new directors

Galapagos NV Announces Board Changes

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Recent updates

Forecast to breakeven in 2024

Third quarter 2024 earnings released: €0.74 loss per share (vs €0.39 profit in 3Q 2023)

Galapagos NV to Report First Half, 2025 Results on Jul 23, 2025

Galapagos NV Announces Board Changes

Investor sentiment improves as stock rises 16%

Galapagos Announces FDA Clearance of IND Application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in Relapsed/Refractory Non-Hodgkin Lymphoma

Second quarter 2024 earnings released

Galapagos NV to Report Fiscal Year 2024 Results on Feb 12, 2025

First quarter 2024 earnings released: EPS: €0.36 (vs €0.35 in 1Q 2023)

Full year 2023 earnings released: €0.061 loss per share (vs €1.09 loss in FY 2022)

Galapagos NV Announces Board Changes

Full year 2023 earnings released: €0.06 loss per share (vs €3.32 loss in FY 2022)

Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG).

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301

Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101

Galapagos NV to Report First Half, 2024 Results on Aug 01, 2024

Third quarter 2023 earnings released: EPS: €0.39 (vs €0.33 in 3Q 2022)

High number of new directors

Galapagos NV Announces Board Changes

Galapagos NV to Report Q4, 2023 Results on Mar 28, 2024

Galapagos NV Announces Start of Phase 2 Study with Selective Tyk2 Inhibitor, GLPG3667, in Patients with Active Systemic Lupus Erythematosus

New major risk - Revenue and earnings growth

Galapagos NV Revises Sales Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: €0.078 (vs €0.29 loss in 2Q 2022)

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Galapagos to Showcase CAR-T Point-Of-Care Manufacturing and Initial Phase 1/2 CLL Data with CD19 CAR-T Candidate, GLPG5201, at the EHA 2023 Congress

First quarter 2023 earnings released: EPS: €0.35 (vs €0.20 loss in 1Q 2022)

Full year 2022 earnings released: €3.32 loss per share (vs €1.92 loss in FY 2021)

Full year 2022 earnings released: €3.32 loss per share (vs €1.92 loss in FY 2021)

Galapagos NV Announces Topline Results from Phase 3 DIVERSITY Trial of Filgotinib in Crohn’s Disease

Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023

Galapagos and CellPoint Presented Encouraging Initial Data AtASH 2022 for GLPG5101, a CD19 CAR-T Candidate Manufactured At Point-Of-Care

Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca® Following Extensive Safety Review of all JAK Inhibitors

Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos NV to Report Fiscal Year 2022 Final Results on Mar 23, 2023

Third quarter 2022 earnings released: EPS: €0.30 (vs €0.99 loss in 3Q 2021)

Galapagos NV to Report Q1, 2023 Results on May 04, 2023

Galapagos Receives Positive CHMP Opinion for Jyseleca® European Label Update Based on Testicular Function Safety Data from MANTA/RAy Studies

Galapagos NV announced that it has received €3.07625 million in funding

Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022

Second quarter 2022 earnings released: €0.29 loss per share (vs €0.98 loss in 2Q 2021)

Galapagos NV (ENXTAM:GLPG) entered into a definitive agreement to acquire Abound Bio, Inc. for $14 million.

Galapagos NV announced that it expects to receive €1.459507 million in funding

High number of new directors

First quarter 2022 earnings released: €0.20 loss per share (vs €0.20 loss in 1Q 2021)

Galapagos NV to Report Q3, 2022 Results on Nov 03, 2022

Galapagos NV Announces Executive Appointments

Galapagos NV Announces Approval of Additional Indication Based on Phase 2B/3 SELECTION Study in Patients with Moderate-To-Severe Ulcerative Colitis

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Galapagos Provides Further Insights into the Treatment of Ulcerative Colitis At the European Crohn’s and Colitis Organization Annual Congress

Galapagos NV Announces Authorization of Medicines and Healthcare Products Regulatory Agency for Jyseleca (Filgotinib), as New Treatment for Ulcerative Colitis in Great Britain

Galapagos Nv Completes Patient Recruitment for Mangrove Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Third quarter 2021 earnings released: €0.64 loss per share (vs €1.25 loss in 3Q 2020)

Galapagos Announces Positive CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Second quarter 2021 earnings released: €0.98 loss per share (vs €1.80 loss in 2Q 2020)

Galapagos NV Demonstrates Early Clinical Activity with SIK2/3 Inhibition in Inflammation

Galapagos NV Announces That Primary and Secondary Endpoint Results from the Phase 3 SELECTIONinduction

Galapagos NV to Present Data on Rheumatoid Arthritis At the Upcoming European League Against Rheumatism (EULAR) Congress

Galapagos Announces First Patient Enrolled in FILOSOPHY Study to Advance Understanding of Jyseleca (Filgotinib) Effectiveness and Safety in A Real-World Setting

Galapagos Reports Primary Endpoint for the Ongoing Filgotinib MANTA and MANTA-RAy Safety Studies

Revenue beats expectations

Galapagos NV to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF

New 90-day low: €73.62

Galapagos NV to Report Fiscal Year 2021 Results on Feb 24, 2022

NICE Recommends Galapagos Jyseleca (Filgotinib) on NHS in Decision for Rheumatoid Arthritis